Salvalaggio, Alessandro
Coraci, Daniele
Obici, Laura
Cacciavillani, Mario
Luigetti, Marco
Mazzeo, Anna
Pastorelli, Francesca
Grandis, Marina
Cavallaro, Tiziana
Bisogni, Giulia
Lozza, Alessandro
Gemelli, Chiara
Gentile, Luca
Russo, Massimo
Ermani, Mario
Fabrizi, Gian Maria
Plasmati, Rosaria
De Napoli, Federica
Campagnolo, Marta
Castellani, Francesca
Salvi, Fabrizio
Fenu, Silvia
Devigili, Grazia
Pareyson, Davide
Gasparotti, Roberto
Rapezzi, Claudio
Martinoli, Carlo
Padua, Luca
Briani, Chiara http://orcid.org/0000-0001-8035-0200
Article History
Received: 20 May 2021
Revised: 17 July 2021
Accepted: 7 August 2021
First Online: 19 August 2021
Conflicts of interest
: Alessandro Salvalaggio reports travel grants from Akcea, Alnylam and Pfizer and consulting honoraria from Alnylam. Laura Obici reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer. Marco Luigetti reports financial grants (honoraria and speaking) from Akcea, Alnylam and Pfizer, and travel grants from Pfizer, Kedrion and Grifols. Gulia Bisogni reports financial grants (honoraria and speaking) from Alnylam and travel grants from Pfizer and Grifols. Gian Maria Fabrizi reports consulting honoraria from Akcea and Alnylam, and travel grants from Kedrion and Alnylam. Chiara Gemelli reports travel grants from Akcea and Pfizer. Carlo Martinoli reports financial relationships (consultant, speaker fees, adv board) with Pfizer, Novartis, Sobi, Takeda and Novonordisk. Chiara Briani reports speaker and consulting honoraria from Akcea, Alnylam and Pfizer, and travel grants from Kedrion, Alnylam and CSL Behring. Davide Pareyson reports financial grants (honoraria and speaking) from Alnylam, Akcea, Pfizer, and Inflectis, and travel grants from Kedrion and Pfizer. Silvia Fenu received financial grants (honoraria and speaking) from Alnylam, Akcea, and Pfizer and travel grants from Alnylam and Akcea. Luca Gentile is sub-investigator in clinical trials of Alnylam, Ionis, Takeda and reports travel grants from Kedrion and CSL Behring financial grants (consulting and speaking) from Pfizer.
: The study was approved by the “<i>Comitato Etico per la Sperimentazione Clinica della Provincia di Padova</i>” (3693/AO/15) and by local ethical committees of all the involved centers.
: All the enrolled subjects gave written informed consent.
: Not applicable.